Toxicity reports of some FDA approved anti-neurodegenerative drugs

Key Points

• To evaluate and report the toxicity levels associated with selected FDA approved neurodegenerative drugs.
• Assessment of toxicity data for two specific anti-neurodegenerative drugs
• Comparison of reported toxicity levels
• Analysis of safety profiles published by the FDA
• Identified significant toxicity levels for both drugs evaluated
• Highlighted specific side effects impacting patient safety
• Reported the need for further investigation into long-term usage risks